home / stock / bmy / bmy articles

BMY Articles, Bristol-Myers Squibb Company

Stock Information
Company Name: Bristol-Myers Squibb Company
Stock Symbol: BMY
Market: NYSE
Menu
BMY BMY Quote BMY Short BMY News BMY Articles BMY Message Board
Get BMY Alerts

News, Short Squeeze, Breakout and More Instantly...
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma | Benzinga

On Thursday, 2seventy Bio Inc. (NASDAQ:TSVT) completed the asset purchase agreement with Novo Nordisk A/S (NYSE:NVO). Under the terms, Novo Nordisk...
FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation | Benzinga

Friday, the FDA granted accelerated approval to Bristol Myers Squibb & Co’s (NYSE:BMY) Krazati (adagrasib) in combination with cetux...

Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments | Benzinga

Gilead Sciences, Inc. (NASDAQ:GILD) witnessed a flurry of Wall Street speculation regarding its potential involvement in the obesity drug market. B...

German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount | Benzinga

German drug developer Evotec SE (NASDAQ:EVO) is reportedly consulting defense advisers following a significant drop in share price, raising concern...
FDA Approves Geron's First Commercial Drug, Competes With Bristol Myers Squibb's Blood Cancer Drug | Benzinga

On Thursday, the FDA approved Geron Corporation's (NASDAQ:GERN) Rytelo (imetelstat) for adult patients with low-to intermediate-1 risk myelody...

Halozyme's ENHANZE Product Gets New Patent Grant in EU | Benzinga

Halozyme Therapeutics (NASDAQ: HALO) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which ...

Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? | Benzinga

Thursday, Replimune Group Inc (NASDAQ:REPL) released topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab i...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers | Benzinga

I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with ...

Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients | Benzinga

Bristol Myers Squibb Co (NYSE:BMY) announced on Tuesday the first presentation of results from the Phase 3 CheckMate -9DW trial evaluatin...

Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday | Benzinga

Bristol Myers Squibb & Co (NYSE:BMY) announced on Saturday (June 1) results from the Phase 3 KRYSTAL-12 study evaluating Krazati (ada...
Next 10